FDA Approves IMFINZI — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's IMFINZI (Durvalumab) for Cancer Treatment AstraZeneca Pharmaceuticals LP has received FDA approval for IMFINZI (durvalumab), an intravenous immunotherapy that strengthens the company's oncology portfolio and positions it to compete in the high-growth immuno-oncology market. The approval expands AstraZeneca's cancer treatment options and is expected to drive significant revenue growth as the drug addresses patient populations with limited treatment alternatives.